Consumer telehealth · Weight-care / GLP-1
Found
Found is a direct-to-consumer telehealth company focused on weight and metabolic care. Clinicians review patients online and medications ship through pharmacy partners when prescribed. Compounded medications are not FDA-approved finished drugs.
Strong fit
- Consumers who want clinician-guided weight care with insurance options where available
- Patients comparing GLP-1 and non-GLP-1 paths with ongoing check-ins
- Buyers who already understand compounded medications are not FDA-approved finished drugs
Weak fit
- Patients who need in-person specialty obesity medicine with local procedures
- Anyone unwilling to diligence pharmacy partners and clinician credentials
- Buyers looking for provider-side clinical software
Bottom line
Found earns a Recommend as a mid-market direct-to-consumer weight-care telehealth brand with clinician review and home delivery. Outcomes for patients are access and protocol convenience more than clinic-grade specialty continuity. Product scope centers on metabolic and weight programs, including GLP-1 options, with the usual compounding caveats when those products are used. Pharmacy-partner review still belongs on the checklist. Pricing is membership plus medication and is more transparent than many enterprise tools. Score sits between Pepti and Henry Meds on our consumer-telehealth board.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Found is a direct-to-consumer telehealth company focused on weight and metabolic care. Patients complete an online intake, meet a clinician, and receive medications through pharmacy partners when prescribed.
Like others in this station, compounded products are not FDA-approved finished drugs. Price and access are the usual reasons patients shop here; specialty continuity with a local obesity clinic is not.
On our consumer-telehealth board Found scores above Henry Meds and near AgelessRx, below Pepti's broader specialty-medication mark.
Competitor landscape
| Vendor | Overall | Ease of use |
|---|---|---|
| Found | 7.4 | 7.2 |
| Pepti | 7.9 | 7.6 |
| AgelessRx | 7.3 | 7.0 |
| Henry Meds | 6.7 | 6.3 |
Pricing
| Item | Detail |
|---|---|
| Model | Membership plus medication; cash-pay and some insurance-supported clinical visit paths depending on plan and state. |
| What usually drives cost | Medication choice (branded vs compounded), dose titration, membership length, and insurance coverage for visits. |
| What to ask in diligence | All-in monthly cost at your likely dose, what happens at refill, and which pharmacy fills the prescription. |
| Published pricing | Public promotional pricing appears on joinfound.com (membership and medication starting points); confirm live checkout totals. |
Compounded GLP-1 products are not FDA-approved finished drugs. Confirm current offerings and pharmacy partners.
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Found to function | |
| Willingness to complete an honest medical intake | Clinicians cannot prescribe safely on incomplete history. |
| Understanding that compounded meds are not FDA-approved finished drugs | Category-wide caveat for many DTC medication programs. |
| A shipping address and ability to receive packages | Fulfillment fails when packages cannot be received. |
| State eligibility for telehealth prescribing | Licensed providers must cover your state. |
| Budget for membership plus medication over months | Titration periods are not one-week projects. |
| What will maximize your value | |
| Track side effects and message the care team early | Ignored symptoms become emergency visits. |
| Compare all-in monthly cost after promotions end | Intro pricing is not the steady price. |
| Confirm which pharmacy fills your prescription | Partner changes affect experience. |
| Keep your primary clinician informed | Split care creates safety gaps. |
| Reassess goals at dose changes | Auto-refills without check-ins waste money. |
| Deal-breakers | |
| You need in-person specialty procedures as the primary treatment. | |
| You refuse to review clinicians and pharmacy partners. | |
| You want only FDA-approved finished drugs and the program cannot meet that. | |
| You are shopping provider EHR software, not a consumer program. | |
| You cannot receive or pay for ongoing medication shipments. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Sign-up → clinician review | Usually days, sometimes about a week depending on labs and state |
| 2 | Clinician review → first shipment | Several days to a couple of weeks depending on pharmacy and meds |
| 3 | First shipment → steady routine | 4-12 weeks of titration and check-ins before a stable cadence |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.